(S)-(1-aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid (S)-1-(2-fluoro-phenyl)-ethyl ester | 942606-12-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-(1-aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid (S)-1-(2-fluoro-phenyl)-ethyl ester
• 英文别名: JN 403；(S)-1-(2-fluorophenyl)ethyl (S)-quinuclidin-3-ylcarbamate；[(1S)-1-(2-fluorophenyl)ethyl] N-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]carbamate
• CAS: 942606-12-4
• 化学式: C₁₆H₂₁FN₂O₂
• 分子量: 292.353
• InChiKey: HQYLURGLNKLOQJ-XHDPSFHLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (S)-(1-aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid (S)-1-(2-fluoro-phenyl)-ethyl ester 在 盐酸 作用下， 以 乙酸乙酯 为溶剂， 反应 1.5h， 以61%的产率得到JN 403 hydrochloride
  参考文献：
  名称：

  Concise Synthesis of JN403, a Novel Nicotinic Acetylcholine Receptor α7 Selective Agonist

  摘要：

  A three-step method for the synthesis of (S)-(1-aza-bicyclo[2.2.2]oct-3-yl)carbamic acid (S)-1-(2-fluorophenyl)ethyl ester HCl salt (12) was developed, starting from alcohol 3 and resulting in an overall yield of 50%. A key feature of the present study is the need to use a strong base such as n-butyllithium for neutralizing the HCl salt of 5 during the condensation of 4 with 5.

  DOI：

  10.1080/00397910802663378
• 作为产物：
  描述：

  (S)-1-(2-氟苯基)乙醇 在 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 7.0h， 生成 (S)-(1-aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid (S)-1-(2-fluoro-phenyl)-ethyl ester
  参考文献：
  名称：

  ANTIPRURITIC AGENT

  摘要：

  一种抗瘙痒药物，基于新颖的作用机制发挥抗瘙痒作用，并对瘙痒有效。该抗瘙痒药物含有一种有效成分，该成分可以激活中枢型尼古丁乙酰胆碱受体。

  公开号：

  US20140128606A1

文献信息

• Combinations of nicotinic acetylcholine alpha 7 receptor agonists
  申请人：Novartis AG

  公开号：EP2135609A1

  公开（公告）日：2009-12-23

  combinations which comprise at least one nicotinic acetylcholine alpha 7 receptor agonist and at least one compound selected from the group consisting of (a) conventional antipsychotics (b) atypical antipsychotics (c) cognition, attention and/or memory enhancers (d) and to use of these combinations in the treatment of psychiatric disorders.

  由至少一种烟碱乙酰胆碱α7 受体激动剂和至少一种选自以下组别的化合物组成的组合物：(a) 传统抗精神病药 (b) 非典型抗精神病药 (c) 认知、注意力和/或记忆增强剂 (d) 以及将这些组合物用于治疗精神病。
• EP2727604A1
  申请人：——

  公开号：EP2727604A1

  公开（公告）日：2014-05-07
• Combinations of Nicotinic Acetylcholine Alpha 7 Receptor Antagonists
  申请人：Kalkman Hans O.

  公开号：US20080306081A1

  公开（公告）日：2008-12-11

  Combinations which comprise at least one nicotinic acetylcholine alpha 7 receptor agonist and at least one compound selected from the group consisting of (a) conventional antipsychotics (b) atypical antipsychotics (c) cognition, attention and/or memory enhancers (d) and to use of these combinations in the treatment of psychiatric disorders.
• COMBINATIONS OF NICOTINIC ACETYLCHOLINE ALPHA 7 RECEPTOR AGONISTS
  申请人：KALKMAN Hans O.

  公开号：US20100125063A1

  公开（公告）日：2010-05-20

  Combinations which comprise at least one nicotinic acetylcholine alpha 7 receptor agonist and at least one compound selected from the group consisting of (a) conventional antipsychotics (b) atypical antipsychotics (c) cognition, attention and/or memory enhancers (d) and to use of these combinations in the treatment of psychiatric disorders.
• USE OF AZABICYCLOALKYL DERIVATIVES OR PYRROLIDINE-2-ONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF ATAXIA
  申请人：Feuerbach Dominik

  公开号：US20120157464A1

  公开（公告）日：2012-06-21

  The invention concerns the use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives for the treatment, prevention or delay of progression of ataxia.